trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Thalidomide is used as a treatment for leprosy.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Thalidomide is used as a treatment for leprosy?

Yes. Thalidomide is widely recognized and used as an effective treatment for erythema nodosum leprosum, a severe inflammatory complication of leprosy.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently confirm that thalidomide is used to treat erythema nodosum leprosum (ENL), a severe immunological complication/reaction associated with leprosy. Multiple studies examine its dosage, efficacy, and role as a comparator or adjuvant therapy. There is no evidence refuting this claim.

Evidence for · 3
Influence of Cytokine-Related genetic variants in TNF, IL6, IL1β, and IFNγ genes in the thalidomide treatment for Erythema nodosum leprosum in a Brazilian population sample.
2025
Get citation
MF, M., RC, S., MF, F., PDSS, C., RR, B., R, V., LM, E., PC, d. M., BS, O. F., SMJ, C., MIDS, S., & FSL, V. (2025). Influence of Cytokine-Related genetic variants in TNF, IL6, IL1β, and IFNγ genes in the thalidomide treatment for Erythema nodosum leprosum in a Brazilian population sample.. doi.org. https://doi.org/10.1016/j.humimm.2025.111260

See more details
More for · 2
Chronic erythema nodosum leprosum in Hansen's disease: a challenging clinical management.
2026
Get citation
M, S., A, B., T, M., C, F., R, F., A, B., E, S., D, M., G, E., G, G., L, Z., & A, B. (2026). Chronic erythema nodosum leprosum in Hansen's disease: a challenging clinical management.. doi.org. https://doi.org/10.1093/trstmh/trag091

Comparison of Relapse Rate and Disease Severity among patients with Type 2 Lepra Reaction receiving Tofacitinib and Thalidomide separately as an adjuvant to systemic steroids: A Longitudinal Analytical Study
2026
Get citation
R, S., BN, N., R, G., G, D., I, M., & S, P. (2026). Comparison of Relapse Rate and Disease Severity among patients with Type 2 Lepra Reaction receiving Tofacitinib and Thalidomide separately as an adjuvant to systemic steroids: A Longitudinal Analytical Study. doi.org. https://doi.org/10.64898/2026.07.07.26357443

What does the evidence say?

The retrieved papers consistently confirm that thalidomide is used to treat erythema nodosum leprosum (ENL), a severe immunological complication/reaction associated with leprosy. Multiple studies examine its dosage, efficacy, and role as a comparator or adjuvant therapy. There is no evidence refuting this claim.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work